文献速递妇科

激素替代治疗对英国女性生存的影响:1984-2017年回顾性队列研究

The effect of hormone replacement therapy on the survival of UK women: a retrospective cohort study 1984-2017.
PubMed 文献 · BJOG · 2021-11-25

该研究基于英国THIN数据库1984-2017年数据,纳入105199名HRT使用者和224643名匹配对照,首次处方年龄46-65岁。平均随访13.5年,共21751例死亡。调整混杂后,联合HRT使用者全因死亡风险降低9%(HR 0.91,95%CI 0.88-0.94),单用雌激素者无显著变化(HR 0.99,95%CI 0.93-1.07)。

要点

  • 联合HRT与全因死亡风险降低9%相关(HR 0.91,95%CI 0.88-0.94)。
  • 单用雌激素与全因死亡风险无显著关联(HR 0.99,95%CI 0.93-1.07)。
  • 联合HRT在51-55岁、56-60岁、61-65岁起始者中死亡风险降低,46-50岁无显著差异。

核心结论

  • 联合HRT与全因死亡风险降低9%相关,单用雌激素未显示显著变化。

研究设计与样本

  • 匹配队列研究,使用英国THIN数据库1984-2017年电子初级保健记录。
  • 纳入105199名HRT使用者(病例)和224643名非使用者(对照),按年龄和全科诊所匹配。
  • 采用Weibull-Double-Cox回归模型,调整首次治疗年龄、出生队列、2型糖尿病、高血压及治疗、冠心病、卵巢切除、子宫切除、体重指数、吸烟和贫困状态。

主要发现

  • 平均随访13.5年,共21751例死亡,其中使用者6329例,非使用者15422例。
  • 联合HRT使用者全因死亡调整HR为0.91(95%CI 0.88-0.94),单用雌激素者为0.99(95%CI 0.93-1.07),均与非使用者比较。
  • 首次治疗年龄46-50、51-55、56-60、61-65岁的联合HRT使用者年龄别调整HR分别为0.98(0.92-1.04)、0.87(0.82-0.92)、0.88(0.82-0.93)、0.92(0.85-0.98)。
  • 单用雌激素者相应年龄别调整HR分别为1.01(0.84-1.21)、1.03(0.89-1.18)、0.98(0.86-1.12)、0.93(0.81-1.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of estrogen-only and combined hormone replacement therapy (HRT) on the hazards of overall and age-specific all-cause mortality in healthy women aged 46-65 at first prescription. DESIGN: Matched cohort study. SETTING: Electronic primary care records from The Health Improvement Network (THIN) database, UK (1984-2017). POPULATION: 105 199 HRT users (cases) and 224 643 non-users (controls) matched on age and general practice. METHODS: Weibull-Double-Cox regression models adjusted for age at first treatment, birth cohort, type 2 diabetes, hypertension and hypertension treatment, coronary heart disease, oophorectomy, hysterectomy, body mass index, smoking and deprivation status. MAIN OUTCOME MEASURES: All-cause mortality. RESULTS: A total of 21 751 women died over an average of 13.5 years follow-up per participant, of whom 6329 were users and 15 422 non-users. The adjusted hazard ratio (HR) of overall all-cause mortality in combined HRT users was 0.91 (95% CI 0.88-0.94), and in estrogen-only users was 0.99 (0.93-1.07), compared with non-users. Age-specific adjusted HRs for participants aged 46-50, 51-55, 56-60 and 61-65 years at first treatment were 0.98 (0.92-1.04), 0.87 (0.82-0.92), 0.88 (0.82-0.93) and 0.92 (0.85-0.98) for combined HRT users compared with non-users, and 1.01 (0.84-1.21), 1.03 (0.89-1.18), 0.98 (0.86-1.12) and 0.93 (0.81-1.07) for estrogen-only users, respectively. CONCLUSIONS: Combined HRT was associated with a 9% lower risk of all-cause mortality and estrogen-only formulation was not associated with any significant changes. TWEETABLE ABSTRACT: Estrogen-only HRT is not associated with all-cause mortality and combined HRT reduces the risks.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Akter N, Kulinskaya E, Steel N, et al. The effect of hormone replacement therapy on the survival of UK women: a retrospective cohort study 1984-2017. BJOG. 2021. PMID: 34773357. doi:10.1111/1471-0528.17008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。